EXAS could have some buyout attraction for such diagnostics companies as LH, DGX, ABT and Roche, who have the resources to try to make Cologuard good enough to be a bona fide SoC for screening the general public. However, these companies probably wouldn’t pay a big premium to EXAS’ existing enterprise value, which has shrunk only slightly since the DeeP-C results were released.
Market Data 
Markets 
AI
